BioTime, Inc. (AMEX:BTX) announced it has entered into an exclusive license agreement with Cornell University for the worldwide development and commercialization of technology developed at Weill Cornell Medical College for the differentiation of human embryonic stem cells into vascular endothelial cells.

BioTime, Inc., a biotechnology company, focuses on regenerative medicine and blood plasma volume expanders.

Read the full article and the disclaimer at: http://drstockpick.com/?p=22092